Noah Goodman

CIK: 0002060075

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (64.3%)

Position reduction

Option Exercises (M)3 (21.4%)

Derivative conversions

Awards (A)2 (14.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KYMR

Kymera Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

KYMR
Kymera Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
3.4K shares at avg. $114.29$387K
KYMR
Kymera Therapeutics, Inc.
Jun 25, 2026
Exercise(M)
Direct
5K shares at avg. $21.05$105K
KYMR
Kymera Therapeutics, Inc.
Jun 25, 2026
Sale(S)
Direct
2.5K shares at avg. $119.00$298K
KYMR
Kymera Therapeutics, Inc.
Jun 25, 2026
Sale(S)
Direct
2.5K shares at avg. $109.00$273K
KYMR
Kymera Therapeutics, Inc.
Jun 22, 2026
Exercise(M)
Direct
2.5K shares at avg. $21.05$53K
KYMR
Kymera Therapeutics, Inc.
Jun 22, 2026
Sale(S)
Direct
2.5K shares at avg. $99.00$248K
KYMR
Kymera Therapeutics, Inc.
Apr 14, 2026
Sale(S)
Direct
1.3K shares at avg. $90.00$121K
KYMR
Kymera Therapeutics, Inc.
Apr 10, 2026
Sale(S)
Direct
2K shares at avg. $87.35$175K
KYMR
Kymera Therapeutics, Inc.
Apr 9, 2026
Exercise(M)
Direct
2.5K shares at avg. $21.05$53K
KYMR
Kymera Therapeutics, Inc.
Apr 9, 2026
Sale(S)
Direct
2.5K shares at avg. $89.00$223K
KYMR
Kymera Therapeutics, Inc.
Apr 9, 2026
Sale(S)
Direct
2.7K shares at avg. $87.11$233K
KYMR
Kymera Therapeutics, Inc.
Apr 9, 2026
Sale(S)
Direct
3.1K shares at avg. $86.62$268K
KYMR
Kymera Therapeutics, Inc.
Mar 2, 2026
Award(A)
Direct
9.2K shares-
KYMR
Kymera Therapeutics, Inc.
Apr 8, 2025
Award(A)
Direct
50K shares-

		Type	Shares	Price		Ownership
Jul 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	3,389	$114.29	$387,329	Direct
Jun 25, 2026	KYMR Kymera Therapeutics, Inc.	Exercise(M)	5,000	$21.05	$105,250	Direct
Jun 25, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	2,500	$119.00	$297,500	Direct
Jun 25, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	2,500	$109.00	$272,500	Direct
Jun 22, 2026	KYMR Kymera Therapeutics, Inc.	Exercise(M)	2,500	$21.05	$52,625	Direct
Jun 22, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	2,500	$99.00	$247,500	Direct
Apr 14, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	1,347	$90.00	$121,230	Direct
Apr 10, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	2,000	$87.35	$174,700	Direct
Apr 9, 2026	KYMR Kymera Therapeutics, Inc.	Exercise(M)	2,500	$21.05	$52,625	Direct
Apr 9, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	2,500	$89.00	$222,500	Direct
Apr 9, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	2,670	$87.11	$232,586	Direct
Apr 9, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	3,094	$86.62	$267,996	Direct
Mar 2, 2026	KYMR Kymera Therapeutics, Inc.	Award(A)	9,225	-	$0	Direct
Apr 8, 2025	KYMR Kymera Therapeutics, Inc.	Award(A)	50,000	-	-	Direct

1-14 of 14 transactions

About Goodman Noah

Goodman Noah (SEC CIK 0002060075) files insider reports with the SEC as Chief Business Officer of Kymera Therapeutics, Inc. (KYMR).

Signal8 holds 8 ownership filings by Goodman Noah (1 Form 3, 7 Form 4), filed between Apr 9, 2025 and Jul 2, 2026. Those filings report 14 transactions, from Apr 8, 2025 to Jul 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Goodman Noah's filings is in WATERTOWN, MA.

Recent filings by Goodman Noah

Jul 1, 2026: Open-market sale of KYMR shares (Form 4, code S).
Jun 25, 2026: Option exercise of KYMR shares (Form 4, code M).
Jun 25, 2026: Open-market sales of KYMR shares (2 lines, Form 4, code S).
Jun 22, 2026: Option exercise of KYMR shares (Form 4, code M).
Jun 22, 2026: Open-market sale of KYMR shares (Form 4, code S).

Other insiders filing for Kymera Therapeutics, Inc. (KYMR)

Mainolfi Nello, Chief Executive Officer
Adams Brian, Chief Legal Officer
Rooney Terence, Chief Medical Officer
Jacobs Bruce N., Chief Financial Officer
Booth Bruce, Director
BVF PARTNERS L P/IL, Director

How to read Form 4 transaction codes